RSS feed

Publications by Ole Petter Børmer

73 publications found

Original articles

Bjerner J, Høgetveit A, Wold Akselberg K, Vangsnes K, Paus E, Bjøro T, Børmer OP, Nustad K (2008)
Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study
Scand J Clin Lab Invest, 68 (8), 703-13
DOI 10.1080/00365510802126836, PubMed 18609108

Bjerner J, Olsen KH, Børmer OP, Nustad K (2005)
Human heterophilic antibodies display specificity for murine IgG subclasses
Clin Biochem, 38 (5), 465-72
DOI 10.1016/j.clinbiochem.2005.02.008, PubMed 15820778

Warren DJ, Bjerner J, Paus E, Børmer OP, Nustad K (2005)
Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies
Clin Chem, 51 (5), 830-8
DOI 10.1373/clinchem.2004.046979, PubMed 15718486

Olsen H, Andersen A, Nordbø A, Kongsgaard UE, Børmer OP (2004)
Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro
BMC Clin Pharmacol, 4, 4
DOI 10.1186/1472-6904-4-4, PubMed 15046641

Bjerner J, Olsen KH, Børmer OP, Nustad K (2004)
Testing and validating a homogeneous immunometric assay for interference
Clin Chem Lab Med, 42 (2), 208-14
DOI 10.1515/CCLM.2004.038, PubMed 15061363

Paus E, Almåsbak H, Børmer OP, Warren DJ (2003)
A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2
J Immunol Methods, 283 (1-2), 125-39
DOI 10.1016/j.jim.2003.08.018, PubMed 14659905

Fosså SD, Aass N, Winderen M, Börmer OP, Olsen DR (2002)
Long-term renal function after treatment for malignant germ-cell tumours
Ann Oncol, 13 (2), 222-8
DOI 10.1093/annonc/mdf048, PubMed 11885998

Bjerner J, Lebedin Y, Bellanger L, Kuroki M, Shively JE, Varaas T, Nustad K, Hammarström S, Børmer OP (2002)
Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 workshop
Tumour Biol, 23 (4), 249-62
DOI 10.1159/000067255, PubMed 12499780

Bjerner J, Nustad K, Norum LF, Olsen KH, Børmer OP (2002)
Immunometric assay interference: incidence and prevention
Clin Chem, 48 (4), 613-21
PubMed 11901059

Høie J, Heimdal K, Nesland JM, Børmer O (2000)
[Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers]
Tidsskr Nor Laegeforen, 120 (27), 3249-52
PubMed 11187163

Børmer OP, Amlie LM, Paus E, Kongsgård U (1999)
Automated albumin method underestimates pharmaceutical-grade albumin in vivo
Clin Chem, 45 (7), 1082-4
PubMed 10388486

Paus E, Nustad K, Børmer OP (1999)
Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen
Tumour Biol, 20 Suppl 1, 52-69
DOI 10.1159/000056531, PubMed 10628410

Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E (1998)
Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia
J Urol, 159 (5), 1599-605
DOI 10.1097/00005392-199805000-00051, PubMed 9554362

Kristinsson J, Røseth A, Fagerhol MK, Aadland E, Schjønsby H, Børmer OP, Raknerud N, Nygaard K (1998)
Fecal calprotectin concentration in patients with colorectal carcinoma
Dis Colon Rectum, 41 (3), 316-21
DOI 10.1007/BF02237485, PubMed 9514426

Nustad K, Paus E, Kierulf B, Børmer OP (1998)
Specificity and affinity of 30 monoclonal antibodies against alpha-fetoprotein
Tumour Biol, 19 (4), 293-300
DOI 10.1159/000030021, PubMed 9679741

Børmer OP, Paus E, Nustad K, Theodorsen L (1994)
[Tumor marker analyses--valuable tools if used correctly]
Tidsskr Nor Laegeforen, 114 (28), 3317-20
PubMed 7809890

Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG (1993)
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
Int J Gynecol Cancer, 3 (5), 299-303
DOI 10.1046/j.1525-1438.1993.03050299.x, PubMed 11578361

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1993)
Serum CA 125 level allows early identification of nonresponders during induction chemotherapy
Gynecol Oncol, 49 (1), 73-9
DOI 10.1006/gyno.1993.1089, PubMed 8482563

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1993)
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Gynecol Oncol, 49 (1), 3-7
DOI 10.1006/gyno.1993.1076, PubMed 8482556

Makar AP, Kristensen GB, Nesland J, Børmer OP, Tropé CG (1993)
Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies
Int J Gynecol Cancer, 3 (2), 116-121
DOI 10.1046/j.1525-1438.1993.03020116.x, PubMed 11578331

Meling GI, Rognum TO, Clausen OP, Børmer O, Lunde OC, Schlichting E, Grüner OP, Hognestad J, Trondsen E, Havig O (1992)
Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients
Scand J Gastroenterol, 27 (12), 1061-8
DOI 10.3109/00365529209028139, PubMed 1475624

Kvale D, Norstein J, Meling GI, Børmer OP, Brandtzaeg P, Langmark F, Rognum TO (1992)
Circulating secretory component in relation to early diagnosis and treatment of liver metastasis from colorectal carcinomas
J Clin Pathol, 45 (7), 568-71
DOI 10.1136/jcp.45.7.568, PubMed 1517455

Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG (1992)
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis
Obstet Gynecol, 79 (6), 1002-10
PubMed 1579296

Makar AP, Kristensen GB, Børmer OP, Tropé CG (1992)
CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
Gynecol Oncol, 45 (3), 323-8
DOI 10.1016/0090-8258(92)90313-8, PubMed 1612511

Nap M, Hammarström ML, Börmer O, Hammarström S, Wagener C, Handt S, Schreyer M, Mach JP, Buchegger F, von Kleist S (1992)
Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen
Cancer Res, 52 (8), 2329-39
PubMed 1559235

Vergote IB, Onsrud M, Børmer OP, Sert BM, Moen M (1992)
CA125 in peritoneal fluid of ovarian cancer patients
Gynecol Oncol, 44 (2), 161-5
DOI 10.1016/0090-8258(92)90032-e, PubMed 1544593

Vergote IB, Abeler VM, Børmer OP, Stigbrand T, Tropé C, Nustad K (1992)
CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma
Tumour Biol, 13 (3), 168-74
DOI 10.1159/000217761, PubMed 1626181

Tanum G, Stenwig AE, Børmer OP, Tveit KM (1992)
Carcinoembryonic antigen in anal carcinoma
Acta Oncol, 31 (3), 333-5
DOI 10.3109/02841869209108181, PubMed 1622654

Børmer OP, Paus E, Nustad K (1991)
Tumour markers as seen from the clinical laboratory: physiological, biochemical, and analytical aspects
Scand J Clin Lab Invest Suppl, 206, 12-20
DOI 10.3109/00365519109107721, PubMed 1947756

Börmer OP, Thrane-Steen K (1991)
Epitope group specificity of six immunoassays for carcinoembryonic antigen
Tumour Biol, 12 (1), 9-15
DOI 10.1159/000217682, PubMed 1705049

Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H (1990)
Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer
Breast Cancer Res Treat, 17 (1), 45-50
DOI 10.1007/BF01812683, PubMed 2151369

Berner A, Børmer O, Marton PF, Nesland JM (1990)
Distribution of the carcinoembryonic antigen CEA in gastric lesions. Immunohistochemical testing of three novel monoclonal antibodies
Histol Histopathol, 5 (2), 199-204
PubMed 2134373

Börmer OP, Nustad K (1990)
Selection of monoclonal antibodies for use in an immunometric assay for carcinoembryonic antigen
J Immunol Methods, 127 (2), 171-8
DOI 10.1016/0022-1759(90)90066-5, PubMed 1690245

Fosså SD, Heilo A, Børmer O (1990)
Unexpectedly high serum methotrexate levels in cystectomized bladder cancer patients with an ileal conduit treated with intermediate doses of the drug
J Urol, 143 (3), 498-501
DOI 10.1016/s0022-5347(17)40001-2, PubMed 2304161

Lindmo T, Børmer O, Ugelstad J, Nustad K (1990)
Immunometric assay by flow cytometry using mixtures of two particle types of different affinity
J Immunol Methods, 126 (2), 183-9
DOI 10.1016/0022-1759(90)90149-p, PubMed 2303729

Dasović-Knezević M, Børmer O, Holm R, Høie J, Sobrinho-Simões M, Nesland JM (1989)
Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies
Mod Pathol, 2 (6), 610-7
PubMed 2587568

Hammarstrom S, Shively JE, Paxton RJ, Beatty BG, Larsson A, Ghosh R, Bormer O, Buchegger F, Mach JP, Burtin P (1989)
Antigenic sites in carcinoembryonic antigen
Cancer Res, 49 (17), 4852-8
PubMed 2474375

Börmer OP (1989)
Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies
J Immunol Methods, 121 (1), 85-93
DOI 10.1016/0022-1759(89)90423-7, PubMed 2502577

Solheim O, Finnanger AM, Stenwig AE, Børmer OP (1988)
[Treatment of diffuse malignant mesothelioma of the pleura]
Tidsskr Nor Laegeforen, 108 (33), 3091-3
PubMed 3206498

Ottestad LO, Tveit KM, Nesland JM, Dybsjord I, Børmer O, Høie J, Pihl A (1988)
An immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay
Histol Histopathol, 3 (3), 269-74
PubMed 2980233

Vergote IB, Børmer OP, Abeler VM (1987)
Evaluation of serum CA 125 levels in the monitoring of ovarian cancer
Am J Obstet Gynecol, 157 (1), 88-92
DOI 10.1016/s0002-9378(87)80352-6, PubMed 2440307

Thorud E, Fosså SD, Vaage S, Kaalhus O, Knudsen OS, Børmer O, Shoaib MC (1986)
Primary breast cancer. Flow cytometric DNA pattern in relation to clinical and histopathologic characteristics
Cancer, 57 (4), 808-11
DOI 10.1002/1097-0142(19860215)57:4<808::aid-cncr2820570421>3.0.co;2-#, PubMed 3943014

Aamdal S, Børmer O, Jørgensen O, Høst H, Eliassen G, Kaalhus O, Pihl A (1984)
Estrogen receptors and long-term prognosis in breast cancer
Cancer, 53 (11), 2525-9
DOI 10.1002/1097-0142(19840601)53:11<2525::aid-cncr2820531126>3.0.co;2-8, PubMed 6713348

Omsjö IH, Wright PB, Börmer OP (1984)
Estrogen and progesterone receptors in normal and malignant vulvar tissue
Gynecol Obstet Invest, 17 (6), 281-3
DOI 10.1159/000299164, PubMed 6745735

von Eyben FE, Skude G, Fosså SD, Klepp O, Børmer O (1983)
Serum lactate dehydrogenase (S-LDH) and S-LDH isoenzymes in patients with testicular germ cell tumors
Mol Gen Genet, 189 (2), 326-33
DOI 10.1007/BF00337825, PubMed 6190072

Kvinnsland S, Børmer O (1982)
[Clinical significance of steroid hormone receptors in breast cancer]
Tidsskr Nor Laegeforen, 102 (34-36), 1866-8
PubMed 7170700

Telhaug R, Fosså SD, Lund G, Børmer O (1982)
[Hormonal treatment of breast cancer in men. Experiences with antiestrogen Tamoxifen]
Tidsskr Nor Laegeforen, 102 (34-36), 1849-51
PubMed 7170693

Fosså SD, Marton PF, Knudsen OS, Kaalhus O, Børmer O, Vaage S (1982)
Nuclear feulgen DNA content and nuclear size in human breast carcinoma
Hum Pathol, 13 (7), 626-30
DOI 10.1016/s0046-8177(82)80004-x, PubMed 7084938

Börmer O (1982)
A direct assay for carcinoembryonic antigen in serum and its diagnostic value in metastatic breast cancer
Clin Biochem, 15 (3), 128-32
DOI 10.1016/s0009-9120(82)90543-4, PubMed 7116619

Kjølseth I, Solheim OP, Klepp O, Børmer O, Sand TE (1979)
[Toxicity of high-dose methotrexate therapy]
Tidsskr Nor Laegeforen, 99 (33), 1708-11
PubMed 531854

Børmer O, Klepp O (1979)
[Spectrum analysis--an evaluation of quality]
Tidsskr Nor Laegeforen, 99 (32), 1655-6
PubMed 531845

Kjörstad KE, Börmer O, Martimbeau P (1977)
Isotope nephrography in carcinoma of the uterine cervix stage I B
Acta Radiol Ther Phys Biol, 16 (3), 219-23
DOI 10.3109/02841867709133939, PubMed 906891

KJORSTAD KE, BORMER O, MARTIMBEAU P (1977)
ISOTOPE NEPHROGRAPHY IN CARCINOMA OF UTERINE CERVIX STAGE-IB
ACTA RADIOL THER PHY, 16 (3), 219-223

Bormer OP (1976)
Purification of a cytotoxic factor from human and rat tissues
Br J Cancer, 34 (4), 359-67
DOI 10.1038/bjc.1976.178, PubMed 987795

Endresen R, Hoel E, Bormer OP (1974)
[Postoperative fluid therapy. A combination of "Normodex" and glucose-saline solution]
Tidsskr Nor Laegeforen, 94 (23), 1385-7
PubMed 4410452

Review articles

Børmer OP (1993)
Immunoassays for carcinoembryonic antigen: specificity and interferences
Scand J Clin Lab Invest, 53 (1), 1-9
DOI 10.3109/00365519309092525, PubMed 7680822

Other articles

Bjerner J, Børmer OP, Nustad K (2005)
The war on heterophilic antibody interference
Clin Chem, 51 (1), 9-11
DOI 10.1373/clinchem.2004.042994, PubMed 15613705

Børmer OP (2001)
Tumor markers in an evidence-based medicine
Scand J Clin Lab Invest, 61 (6), 417-9
DOI 10.1080/00365510152567040, PubMed 11681530

Stenman UH, Paus E, Allard WJ, Andersson I, Andrès C, Barnett TR, Becker C, Belenky A, Bellanger L, Pellegrino CM, Børmer OP, Davis G, Dowell B, Grauer LS, Jette DC, Karlsson B, Kreutz FT, van der Kwast TM, Lauren L, Leinimaa M, Leinonen J, Lilja H, Linton HJ, Nap M, Hilgers J (1999)
Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen
Tumour Biol, 20 Suppl 1, 1-12
DOI 10.1159/000056523, PubMed 10628402

Børmer OP (1998)
[Follow-up after colorectal cancer. Undeserved neglect of CEA-analysis]
Tidsskr Nor Laegeforen, 118 (18), 2825-6
PubMed 9748821

Nustad K, Bast RC, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J (1996)
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine
Tumour Biol, 17 (4), 196-219
DOI 10.1159/000217982, PubMed 8685601

Nap M, Vitali A, Nustad K, Bast RC, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Børmer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarström S, Kenemans P, Hilgers J (1996)
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop
Tumour Biol, 17 (6), 325-31
PubMed 8938947

Børmer OP, Paus E (1994)
[Prostate-specific antigen and prostatic cancer]
Tidsskr Nor Laegeforen, 114 (6), 710-1
PubMed 7514820

Børmer OP (1994)
From tissue polypeptide antigen to specific cytokeratin assays
Tumour Biol, 15 (4), 185-7
DOI 10.1159/000217891, PubMed 7524129

Börmer OP (1991)
Major disagreements between immunoassays of carcinoembryonic antigen may be caused by nonspecific cross-reacting antigen 2 (NCA-2)
Clin Chem, 37 (10 Pt 1), 1736-9
PubMed 1914175

Börmer OP (1991)
Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen
Clin Chem, 37 (2), 231-6
PubMed 1993329

Fosså SD, Tveit K, Börmer O, Moxnes A, Jørgensen NP, Orjaseter H, Kristoffersen DT (1988)
Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations
Eur J Clin Pharmacol, 34 (5), 517-9
DOI 10.1007/BF01046713, PubMed 3203714

BORMER O, NUSTAD K, PAUS E (1987)
CLINICAL UTILITY OF TUMOR-MARKERS
Scand. J. Clin. Lab. Invest., 47 (3), 301-302

BORMER O (1984)
PROGESTERONE RECEPTORS AS A PROGNOSTIC FACTOR IN STAGE-II BREAST-CANCER
N. Engl. J. Med., 310 (20), 1324-1325

Telhaug R, Klepp O, Børmer O (1982)
Phase II study of tamoxifen in patients with metastatic malignant melanoma
Cancer Treat Rep, 66 (6), 1437
PubMed 7083247

Books

Heier HE, Børmer OP (2003)
Transfusjonshåndbok: aktuelle produkter, indikasjoner, transfusjonsprosedyrer,komplikasjoner
Blodbanken i Oslo, [Oslo] ([Rev. utg.]), 43 s.
BIBSYS 031826296

Heier HE, Børmer OP (1997)
Transfusjonshåndbok: aktuelle produkter, indikasjoner, transfusjonsprosedyrer,komplikasjoner
Blodbanken, [Oslo], 44 s.
BIBSYS 972481192

Theses

Børmer OP (1992)
Immunoassays for carcinoembryonic antigen: specificity and interferences
Central Laboratory, The Norwegian Radium Hospital and Norwegian Cancer Society, [Oslo], 1 b. (flere pag.)
BIBSYS 920420125, ISBN 82-7633-014-2